VYNE
VYNE Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.56
+0.00%Margins
Gross margin
99.4%
EBITDA margin
-4785.2%
EBIT margin
-4877.1%
Net margin
-4417.3%
FCF margin
-1773.1%
—
Return on equity
—
Return on assets
—
Return on invested capital
0.07x
Asset turnover
-$16.9M
Cash from operations
$0.04
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026